SCHEMBL2817652

SCHEMBL2817652

COc1ccc(C(=O)Nc2ccc(C3(C(=O)N4CCOCC4)CCCC3)cc2)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.69
KDM4E B2RXH2 2/20 0.67
MAPT P10636 4/20 0.64
MEN1 O00255 3/20 0.64
ALDH1A1 P00352 3/20 0.64
PKM P14618 1/20 0.64
CYP2C19 P33261 2/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
USP2 O75604 2/20 0.58
HDAC1 Q13547 1/20 0.55
POLB P06746 2/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TP53 P04637 1/20 0.53
THRB P10828 1/20 0.53
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4436370 0.85 KMT2A (0.51) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2819698 0.82 KMT2A (0.80) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2817570 0.82 KMT2A (0.76) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2815432 0.82 KMT2A (0.76) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2814616 0.82 KMT2A (0.76) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2819535 0.81 KMT2A (1.00) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2819794 0.79 KMT2A (0.72) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2815498 0.75 KMT2A (0.67) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2814882 0.74 KMT2A (0.64) KMT2AKDM4EMAPTMEN1ALDH1A1
SCHEMBL2816115 0.74 KMT2A (0.66) KMT2AKDM4EMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US disclosed
CN-101679215-A New benzamide derivatives as the follicle stimulating hormone conditioning agent ADDEX PHARMA SA 2010-03-24 CN disclosed
EP-2134676-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE Addex Pharma SA (CH) 2009-12-23 EP disclosed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE FSHR, GNRHR, SHBG KMT2A 1767/4885KDM4E 1395/4885MAPT 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.